BACKGROUND: Interactions between antiretroviral (ARV) therapy and medications to treat age-related comorbidities are a growing concern in the aging HIV population. OBJECTIVE: To investigate the association of age with potential drug-drug interactions (PDDIs) involving ARVs. METHODS: We studied ARV-treated patients attending a tertiary care center. PDDIs were classified as "red flag" (contraindicated) or "orange flag" (use with caution or dose adjustment). Logistic regression was used to determine the association of age with the occurrence of ≥1 PDDI. RESULTS: Of 914 patients (78% male, median age 49 years), older patients (age ≥50 years) were on more drugs than younger patients (total 9 vs 7; P < .0001) and were more likely to be on ritonavir-boosted protease inhibitors (PIs), integrase inhibitors, and non-ARV medications. Older patients were more likely to have ≥1 orange flag PDDI (71% vs 55%, P < .0001) and to have a red flag PDDI (5% vs 2%, P = .07), although the latter did not reach statistical significance. A 10-year increase in age was associated with an increased likelihood of ≥1 PDDI (odds ratio [OR] = 1.72; P < .0001) after adjusting for gender, race and number and class of ARVs. The effect of age was diminished after adjusting further for the number of non-ARV medications (OR = 1.28; P = .02) and use of cardiovascular drugs (OR = 1.16; P = .21). CONCLUSIONS: In our clinic population, older patients were more likely to have a PDDI because of the greater number of non-ARV medications, particularly cardiovascular agents.
BACKGROUND: Interactions between antiretroviral (ARV) therapy and medications to treat age-related comorbidities are a growing concern in the aging HIV population. OBJECTIVE: To investigate the association of age with potential drug-drug interactions (PDDIs) involving ARVs. METHODS: We studied ARV-treated patients attending a tertiary care center. PDDIs were classified as "red flag" (contraindicated) or "orange flag" (use with caution or dose adjustment). Logistic regression was used to determine the association of age with the occurrence of ≥1 PDDI. RESULTS: Of 914 patients (78% male, median age 49 years), older patients (age ≥50 years) were on more drugs than younger patients (total 9 vs 7; P < .0001) and were more likely to be on ritonavir-boosted protease inhibitors (PIs), integrase inhibitors, and non-ARV medications. Older patients were more likely to have ≥1 orange flag PDDI (71% vs 55%, P < .0001) and to have a red flag PDDI (5% vs 2%, P = .07), although the latter did not reach statistical significance. A 10-year increase in age was associated with an increased likelihood of ≥1 PDDI (odds ratio [OR] = 1.72; P < .0001) after adjusting for gender, race and number and class of ARVs. The effect of age was diminished after adjusting further for the number of non-ARV medications (OR = 1.28; P = .02) and use of cardiovascular drugs (OR = 1.16; P = .21). CONCLUSIONS: In our clinic population, older patients were more likely to have a PDDI because of the greater number of non-ARV medications, particularly cardiovascular agents.
Entities:
Keywords:
HIV; antiretroviral therapy; drug interaction
Authors: Nimish Patel; Michael Veve; Mona Nasiri; Steven Bliss; Louise-Anne McNutt; Victoria Lazariu; Christopher Miller Journal: AIDS Patient Care STDS Date: 2014-08-05 Impact factor: 5.078
Authors: Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash Journal: AIDS Patient Care STDS Date: 2019-03 Impact factor: 5.078
Authors: Monty Montano; Shalender Bhasin; Richard T D'Aquila; Kristine M Erlandson; William J Evans; Nicholas T Funderburg; Amy Justice; Lishomwa C Ndhlovu; Bisola Ojikutu; Marco Pahor; Savita Pahwa; Alice S Ryan; Jennifer Schrack; Michael B Schultz; Paola Sebastiani; David A Sinclair; Julia Tripp; Bruce Walker; Julie A Womack; Raymond Yung; R Keith Reeves Journal: AIDS Res Hum Retroviruses Date: 2019-09-23 Impact factor: 2.205
Authors: Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Jonathan V Todd; Stephen R Cole; David A Wohl; Ross J Simpson; Michele Jonsson Funk; M Alan Brookhart; Jennifer Cocohoba; Daniel Merenstein; Anjali Sharma; Jason Lazar; Joel Milam; Mardge Cohen; Stephen Gange; Tené T Lewis; Greer Burkholder; Adaora A Adimora Journal: AIDS Patient Care STDS Date: 2017-11 Impact factor: 5.078